Intervention 1: Intervention group: Standard treatment (Flosalmax inhaler, two puffs every 12 hours

2 trials

Sponsors

Shahre-kord University of Medical Sciences

Conditions

Chronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary disease, unspecifiedPulmonary hypertension secondary to chronic obstructive pulmonary disease. Pulmonary heart disease, unspecified

Phase 2

Effect of Empagliflozin on Pulmonary Arterial Hypertension Secondary to COPD

Active, not recruitingIRCT20250908067192N1

Shahre-kord University of Medical SciencesPulmonary hypertension secondary to chronic obstructive pulmonary disease. Pulmonary heart disease, unspecified

Start: 2025-11-12Target: 72Updated: 2025-10-13

The Effect of Empagliflozin on Spirometric Indices in Patients With Chronic Obstructive Pulmonary Disease

RecruitingIRCT20251127068134N1

Shahre-kord University of Medical SciencesChronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary disease, unspecified

Start: 2026-01-20Target: 72Updated: 2026-02-02